Paul B. Manning - 30 Jun 2021 Form 3 Insider Report for Acumen Pharmaceuticals, Inc. (ABOS)

Role
10%+ Owner
Signature
/s/ Katherine Denby, Attorney-in-Fact
Issuer symbol
ABOS
Transactions as of
30 Jun 2021
Net transactions value
$0
Form type
3
Filing time
30 Jun 2021, 19:11:30 UTC
Previous filing
21 Jun 2021
Next filing
08 Jul 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ABOS Common Stock 89,709 30 Jun 2021 See Footnotes F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ABOS Series A-1 Preferred Stock 30 Jun 2021 Common Stock 1,634,515 See Footnote F1, F2
holding ABOS Series B Preferred Stock 30 Jun 2021 Common Stock 1,315,969 See Footnote F1, F2
holding ABOS Series B Preferred Stock 30 Jun 2021 Common Stock 657,985 See Footnote F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The securities are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust.
F2 Each share of Series A-1 Preferred Stock and each share of Series B Preferred Stock will automatically convert into one share of Common Stock of the Issuer upon the closing of the Issuer's initial public offering. The Series A-1 Preferred and the Series B Preferred Stock have no expiration date.
F3 The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB.

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney